Journal of Cataract & Refractive Surgery
Volume 34, Issue 6 , Pages 902-908 , June 2008

Corneal endothelial cell injury induced by mitomycin-C in photorefractive keratectomy: Nonrandomized controlled trial

,Accepted 2 March 2008.

References 

  1. Kim JH, Kim MS, Hahn TW, Lee YC, Sah WJ, Park CK. Five year results of photorefractive keratectomy for myopia. J Cataract Refract Surg. 1997;23:731–735
  2. Haviv D, Hefez L, Krakowsky D, Abrahami S, Kibarski U, Nemet P. For how long can regression continue after photorefractive keratectomy for myopia?. Ophthalmology. 1997;104:1948–1950discussion by JH Talamo, 1950–1951
  3. Møller-Pedersen T, Cavanagh HD, Petroll WM, Jester JV. Stromal wound healing explains refractive instability and haze development after photorefractive keratectomy; a 1-year confocal microscopic study. Ophthalmology. 2000;107:1235–1245
  4. Alió JL, Artola A, Claramonte PJ, Ayala MJ, Sánchez SP. Complications of photorefractive keratectomy for myopia: two year follow-up of 3000 cases. J Cataract Refract Surg 1998; 24:619–626
  5. Brilakis HS, Deutsch TA. Topical tetracaine with bandage soft contact lens pain control after photorefractive keratectomy. J Refract Surg. 2000;16:444–447
  6. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic agents. In:  Hardman JG,  Limbird LE editor. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed.. New York, NY: McGraw Hill; 2001;p. 1389–1459
  7. Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology. 1991;98:317–321
  8. Mahar PS, Nwokora GE. Role of mitomycin C in pterygium surgery. Br J Ophthalmol. 1993;77:433–435
  9. Helal M, Messiha N, Amayem A, El-Maghraby A, Elsherif Z, Dabees M. Intraoperative mitomycin-C versus postoperative topical mitomycin-C drops for the treatment of pterygium. Ophthalmic Surg Lasers. 1996;27:674–678
  10. Wilson MW, Hungerford JL, George SM, Madreperla SA. Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am J Ophthalmol. 1997;124:303–311
  11. Frucht-Pery J, Sugar J, Baum J, Sutphin JE, Pe'er J, Savir H, et al. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia; a multicenter experience. Ophthalmology. 1997;104:2085–2093discussion by PR Laibson, 2093
  12. Donnenfeld ED, Perry HD, Wallerstein A, Coronia RM, Kanellopoulos AJ, Sforza PD, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Ophthalmology. 1999;106:72–78discussion by MB Raizman, 79
  13. Talamo JH, Gollamudi S, Green WR, de la Cruz Z, Filatov V, Stark WJ. Modulation of corneal wound healing after excimer laser keratomileusis using topical mitomycin C and steroids. Arch Ophthalmol. 1991;109:1141–1146
  14. Schipper I, Suppelt C, Gebbers J-O. Mitomycin C reduces scar formation after excimer laser (193 nm) photorefractive keratectomy in rabbits. Eye. 1997;11:649–655
  15. Majmudar PA, Forstot SL, Dennis RF, Nirankari VS, Damiano RE, Brenart R, et al. Topical mitomycin C for subepithelial fibrosis after refractive corneal surgery. Ophthalmology. 2000;107:89–94
  16. Carones F, Vigo L, Scandola E, Vacchini L. Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratecomy. J Cataract Refract Surg. 2002;28:2088–2095
  17. Jain S, McCally RL, Connolly PJ, Azar DT. Mitomycin C reduces corneal light scattering after excimer keratectomy. Cornea. 2001;20:45–49
  18. Lee DH, Chung HS, Jeon YC, Boo SD, Yoon YD, Kim JG. Photorefractive keratectomy with intraoperative mitomycin-C application. J Cataract Refract Surg. 2005;31:2293–2298
  19. Bedei A, Marabotti A, Giannecchini I, Ferretti C, Montagnani M, Martinucci C, et al. Photorefractive keratectomy in high myopic defects with or without intraoperative mitomycin C: 1-year results. Eur J Ophthalmol. 2006;16:229–234
  20. Gambato C, Ghirlando A, Moretto E, Busato F, Midena E. Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology. 2005;112:208–218discussion by RS Rubinfeld, 219
  21. Xu H, Liu S, Xia X, Huang P, Wang P, Wu X. Mitomycin C reduces haze formation in rabbits after excimer photorefractive keratectomy. J Refract Surg. 2001;17:342–349
  22. Kim T-I, Tchah H, Lee S-A, Sung K, Cho BJ, Kook MS. Apoptosis in keratocytes caused by mitomycin C. Invest Ophthalmol Vis Sci. 2003;44:1912–1917Available at: http://www.iovs.org/cgi/reprint/44/5/1912Accessed March 13, 2008
  23. Kim TI, Pak JH, Lee SY, Tchah H. Mitomycin C-induced reduction of keratocytes and fibroblasts after photorefractive keratectomy. Invest Ophthalmol Vis Sci. 2004;45:2978–2984Available at: http://www.iovs.org/cgi/reprint/45/9/2978Accessed March 13, 2008
  24. Sadeghi HM, Seitz B, Hayashi S, Labree L, McDonnell PJ. In vitro effects of mitomycin-C on human keratocytes. J Refract Surg. 1998;14:534–540
  25. Kim T-I, Lee SY, Pak JH, Tchah H, Kook MS. Mitomycin C, ceramide, and 5-fluorouracil inhibit corneal haze and apoptosis after PRK. Cornea. 2006;25:55–60
  26. Netto MV, Mohan RR, Sinha S, Sharma A, Gupta PC, Wilson SE. Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze and long-term keratocyte density in rabbits. J Refract Surg. 2006;22:562–574
  27. Rubinfeld RS, Pfister RR, Stein RM, Foster CS, Martin NF, Stoleru S, et al. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology. 1992;99:1647–1654
  28. Seah SKL, Prata JA, Minckler DS, Koda RT, Baerveldt G, Lee PP, et al. Mitomycin-C concentration in human aqueous humour following trabeculectomy. Eye. 1993;7:652–655
  29. Smith S, D'Amore PA, Dreyer EB. Comparative toxicity of mitomycin C and 5-fluorouracil in vitro. Am J Ophthalmol. 1994;118:332–337
  30. McDermott ML, Wang J, Shin DH. Mitomycin and the human corneal endothelium. Arch Ophthalmol. 1994;112:533–537
  31. McKelvie PA, Daniell M. Impression cytology following mitomycin C therapy for ocular surface squamous neoplasia. Br J Ophthalmol. 2001;85:1115–1119
  32. Dogru M, Erturk H, Shimazaki J, Tsubota K, Gul M. Tear function and ocular surface changes with mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia. Cornea. 2003;22:627–639
  33. Parikh CH, Edelhauser HF. Ocular surgical pharmacology: corneal endothelial safety and toxicity. Curr Opin Ophthalmol. 2003;14:178–185
  34. Dudney BW, Malecha MA. Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia. Am J Ophthalmol. 2004;137:950–951
  35. Kim T-I, Tchah H, Cho EH, Kook MS. Evaluation for safety of cultured corneal fibroblasts with cotreatment of alcohol and mitomycin C. Invest Ophthalmol Vis Sci. 2004;45:86–92Available at: http://www.iovs.org/cgi/reprint/45/1/86Accessed March 13, 2008
  36. Chang S-W. Early corneal edema following topical application of mitomycin-C. J Cataract Refract Surg. 2004;30:1742–1750
  37. Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol. 2006;90:819–822Available at: http://bjo.bmj.com/cgi/reprint/90/7/819Accessed March 13, 2008
  38. Morales AJ, Zadok D, Mora-Retana R, Martínez-Gama E, Robledo NE, Chayet AS. Intraoperative mitomycin and corneal endothelium after photorefractive keratectomy. Am J Ophthalmol. 2006;142:400–404
  39. Sihota R, Sharma T, Agarwal HC. Intraoperative mitomycin C and the corneal endothelium. Acta Ophthalmol Scand. 1998;76:80–82
  40. Dreyer EB, Chaturvedi N, Zurakowski D. Effect of mitomycin C and fluorouracil-supplemented trabeculectomies on the anterior segment. Arch Ophthalmol. 1995;113:578–580
  41. van Schaick W, van Dooren BTH, Mulder PGH, Völker-Dieben HJM. Validity of endothelial cell analysis methods and recommendations for calibration in Topcon SP-2000P specular microscopy. Cornea. 2005;24:538–544
  42. Oblak E, Doughty MJ, Oblak L. A semi-automated assessment of cell size and shape in monolayers, with optional adjustment for the cell–cell border width—application to human corneal endothelium. Tissue Cell. 2002;34:283–295
  43. Hurst LW, Ferris FL, Stark WJ, Fleishman JA. Clinical specular microscopy. [editorial] Invest Ophthalmol Vis Sci. 1980;19:2–4Available at: http://www.iovs.org/cgi/reprint/19/1/2Accessed March 13, 2008
  44. Nassaralla BA, McLeod SD, Nassaralla JJ. Prophylactic mitomycin C to inhibit corneal haze after photorefractive keratectomy for residual myopia following radial keratotomy. J Refract Surg. 2007;23:226–232
  45. Smith DL, Skuta GL, Lindenmuth KA, Musch DC, Bergstrom TJ. The effect of glaucoma filtering surgery on corneal endothelial cell density. Ophthalmic Surg. 1991;22:251–255
  46. Dushku N, Reid TW. Immunohistochemical evidence that human pterygia originate from an invasion of vimentin-expressing altered limbal epithelial basal cells. Curr Eye Res. 1994;13:473–481
  47. Chang S-W, Tsai I-L, Hu F-R, Lin LL-K, Shih Y-F. The cornea in young myopic adults. Br J Ophthalmol. 2001;85:916–920
  48. Torres RM, Merayo-Lloves J, Daya SM, Blanco-Mezquita JT, Espinosa M, Nozal MJ, et al. Presence of mitomycin-C in the anterior chamber after photorefractive keratectomy. J Cataract Refract Surg. 2006;32:67–71
  49. Dorr RT. New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C. Semin Oncol. 1988;15:S32–S41
  50. Kawase K, Matsushita H, Yamamoto T, Kitazawa Y. Mitomycin concentration in rabbit and human ocular tissues after topical administration. Ophthalmology. 1992;99:203–207
  51. Fujitani A, Hayasaka S, Shibuya Y, Noda S. Corneoscleral ulceration and corneal perforation after pterygium excision and topical mitomycin C therapy. Ophthalmologica. 1993;207:162–164

 No author has a financial or proprietary interest in any material or method mentioned.

PII: S0886-3350(08)00300-3

doi: 10.1016/j.jcrs.2008.03.007

Journal of Cataract & Refractive Surgery
Volume 34, Issue 6 , Pages 902-908 , June 2008

Article Tools

* Image Usage & Resolution